Skip to main content
SpringerLink
Log in
Book cover

LH-RH Agonists in Oncology pp 22–29Cite as

Direct Antitumor Effects of an LH-RH Agonist

  • Conference paper

Abstract

Chronic administration of potent long-acting luteinizing hormone-releasing hormone (LH-RH) agonists to patients in sufficiently high doses causes a chemical castration through suppression of the pituitary-gonadal axis. This therapy appears effective in the treatment of hormone-dependent tumors, such as breast and prostate cancer (for updated results, see the chapters in this volume).

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klijn JGM (1987) LH-RH agonists in the treatment of metastatic breast cancer: 5 years experience (this volume)

    Google Scholar 

  2. Eidne KA, Flanagan CA, Miller RP (1985) Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989–992

    Article  PubMed  CAS  Google Scholar 

  3. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233

    Article  PubMed  CAS  Google Scholar 

  4. Miller WR, Scott WN, Fraser HM, Scharpe RM (1987) Direct inhibition of human breast cancer cell growth by an LH-RH agonist. In: Klijn JGM, Paridaens R, Foekens JA (eds)Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents, EORTC Monograph Series, Raven Press, New York Vol 18, pp 357–368

    Google Scholar 

  5. Sehally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatments of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289

    Google Scholar 

  6. Harvey HA, Lipton A, Max DT (1984) LH-RH analogs for human mammary carcinoma. In: Vickery BH, Nestor JJ, Hafex ESE (eds) LH-RH and its analogues, contraceptive and clinical application. MTP, Lancaster, pp 329–338

    Google Scholar 

  7. Harvey HA, Lipton A, Max D (1986) LH-RH agonist treatment of breast cancer: a phase II study in the USA. Eur J Cancer Clin Oncol 22: 724

    Google Scholar 

  8. Mathé G, Keiling R, Vovan ML, Gastiaburu J, Prévôt G, Vannetzel JM, Despax R, Jasmin C, Lévi F, Musset M, Machover D, Misset JL (1986) Phase II trial of D-Trp-6-LH-RH in advanced breast cancer. Eur J Cancer Clin Oncol 22: 723

    Article  Google Scholar 

  9. Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in postmenopausal women with luteinizing hormone releasing hormone (ICI 118630) therapy. Eur J Cancer Clin Oncol 22: 746

    Article  Google Scholar 

  10. Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15: 171–173

    Article  PubMed  CAS  Google Scholar 

  11. Klijn JGM, Foekens JA (1987) Long-term peptide hormone treatment with LH-RH-agonists in metastatic breast cancer. In: Santen R (ed) Proceedings of the International Symposium on Endocrine-dependent breast cancer: critical assessment of recent advances, 14th Int Congress, 23 Aug 1986, Budapest (in press)

    Google Scholar 

  12. Manni A, Santen R, Harvey H, Lipton A, Max D (1986) Treatment of breast cancer with gonadotropin releasing hormone. Endocr Rev 7: 89–94

    Article  PubMed  CAS  Google Scholar 

  13. Nicholson RI, Walker KJ, Turkes A, Dyas J, Plowman PN, Williams M, Elston CW, Blarney PW (1987) The British experience with LH-RH agonist Zoladex (ICI-118630) in the treatment of breast cancer. In: Klijn JGM, Paridaens R, Foekens J A (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents, EORTC Monograph Series, Raven Press, New York, Vol 18, pp 331–341

    Google Scholar 

  14. Nicholson RI, Walker KJ, Turkes A, Dyas J, Plowman PN, Williams M, Blarney RW (1985) Endocrinological and clinical aspects of LH-RH action (ICI-118630) in hormone dependent breast cancer. J Steroid Biochem 23: 843–844

    Article  PubMed  CAS  Google Scholar 

  15. Blankenstein MA, Henkelman MS, Klijn JGM (1983) An analogue of LH-RH antagonizes the growth-stimulation effect of oestradiol in human breast cancer cells in culture (MCF-7). J Steroid Biochem [Suppl] 19: 95S

    Google Scholar 

  16. Blankenstein MA, Henkelman MS, Klijn JGM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21: 1493–1499

    Article  PubMed  CAS  Google Scholar 

  17. Foekens JA, Henkelman MS, Bolt-de Vries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LH-RH analogs on breast and prostatic tumor cells. In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents, EORTC Monograph Series, Raven Press, New York, Vol 18, pp 369–380

    Google Scholar 

  18. Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochem Biophys Res Commun 140: 550–556

    Article  PubMed  CAS  Google Scholar 

  19. Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LH-RH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873

    Article  PubMed  CAS  Google Scholar 

  20. Wiznitzer I, Benz C (1984) Direct growth inhibiting effects of the prolactin antagonists Buserelin and Pergolide on human breast cancer. Proc Am Assoc Cancer Res 25: 208

    Google Scholar 

  21. Schalley AV, Redding TW (1987) Use of LH-RH analogs for the treatment of prostate cancer: combination therapy and direct effects. In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents, EORTC Monograph Series, Raven Press, New York (in press)

    Google Scholar 

  22. Besthois Y, Katzenellebogen JA, Katzenellebogen BS (1986) Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500

    Article  Google Scholar 

  23. Klijn JGM, Setyono-Han B, Bakker GH, Henkelman MS, Foekens JA (1987) Inhibition of the growth of human breast cancer cells (MCF-7) in vitro and of DMB A tumors in vivo by an analog of somatostatin (Sandostatin): possible involvement of somatostatin receptors. In: Santen R (ed) Proceedings of the International Symposium on Endocrine-dependent breast cancer: critical assessment of recent advances, 14th Int Congress, 23 Aug 1986, Budapest (in press)

    Google Scholar 

  24. Klijn JGM, Setyono-Han B, Bakker GH, Henkelman MS, Portengen H, Foekens JA (1987) Effects of somatostatin analog (Sandostatin) treatment in experimental and human cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Proceedings of the International Symposium on Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents, EORTC Monograph Series, Raven Press, New York, Vol 18, pp 459–468

    Google Scholar 

  25. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM (1987) Direct inhibitory effects of somatostatin (analogs) on the growth of human breast cancer cells. Cancer Res (in press)

    Google Scholar 

  26. Westley B, Rochefort H (1979) Estradiol induced proteins in the MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 90: 410–416

    Article  PubMed  CAS  Google Scholar 

  27. Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H (1985) Estrogen-specific proteins released by breast cancer cells in culture and control of cell proliferation. In: Hollander, VP (ed) Hormonally responsive tumors. Academic Press, Orlando, Florida, pp 135–153

    Google Scholar 

  28. Dickson RB, Huff KK, Spencer EM, Lippman ME (1986) Induction of epidermal growth factor- related polypeptides by 17 (ß-estradiol in MCF-7 human breast cancer cells. Endocrinology 118: 138–142

    Article  PubMed  CAS  Google Scholar 

  29. Dickson RB, Bates SE, McManaway ME, Lippman ME (1986) Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46: 1707–1713

    PubMed  CAS  Google Scholar 

  30. Lippman ME, Dickson RB, Bates S, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelman EP (1986) Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7: 59–70

    Article  PubMed  CAS  Google Scholar 

  31. Horwitz KB, Koseki Y, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742–1751

    Article  PubMed  CAS  Google Scholar 

  32. Eckert RL, Katzenellebogen BS (1982) Effects of estrogens and anti-estrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 42: 139–144

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. A. Foekens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. G. M. Klijn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstr. 55, D-4300, Essen 1, Federal Republic of Germany

    Klaus Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Foekens, J.A., Klijn, J.G.M. (1988). Direct Antitumor Effects of an LH-RH Agonist. In: Höffken, K. (eds) LH-RH Agonists in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73530-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73530-1_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73532-5

  • Online ISBN: 978-3-642-73530-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation